Cordyceps sinensis and Sonodynamic Therapy in Non-Small Cell Lung Cancer: Pharmacological Basis, Therapeutic Potential, and Future Directions.

Non-small cell lung cancer (NSCLC) accounts for the highest cancer-related mortality worldwide. Chemotherapy, the backbone of treatment for advanced disease, is constrained by drug resistance and off-target toxicity. Extracts of Cordyceps sinensis (CORS), a medicinal fungus, contain cordycepin, cordyceps polysaccharides (CSP), and various sterols that suppress NSCLC cell proliferation and induce apoptosis in preclinical models. Translating these findings to the clinic, however, faces three problems. First, the active compounds are poorly absorbed orally. Second, water-based decoction inevitably co-extracts inorganic arsenic at roughly four times the Chinese Pharmacopoeia limit. Third, CORS components lack tumor-targeting capability. We propose combining purified cordycepin and CSP with magnetic PLGA-PEG nanoparticles loaded with superparamagnetic iron oxide (SPIO), using an external magnet to concentrate the nanoparticles at the tumor and focused ultrasound to do two things at once: mechanically disrupt the polymer matrix to release the drug payload, and where a sonosensitizer is co-loaded, generate cytotoxic reactive oxygen species (ROS). We also address a practical hurdle: ultrasound attenuates massively in aerated lung. We review workarounds including endobronchial ultrasound, lower frequencies, and microbubble-enhanced cavitation. Compared with immune checkpoint inhibitors, which require PD-L1 positivity and carry a risk of serious immune-related adverse events, our platform operates through multi-targeted mechanisms independent of a single biomarker. Sonodynamic ROS may also induce immunogenic cell death, suggesting potential synergy with immunotherapy.In our view, this nano-enabled approach to traditional Chinese medicine represents one way to bring the pharmacology of CORS into the era of evidence-based oncology.